**Table 1. Changes over time in some parameters in chronic hepatitis B patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **At baseline** | **On ARV** | **P value** |
| Age, years | 49.0 (32.0–58.0) | 51.0 (33.0–59.0) | < 0.001 |
| Gender | | | |
| Male | 23 (54.8%) | – | – |
| Female | 19 (45.2%) | – |
| HBeAg positive | 7 (16.7%) | 3 (7.1%) | 0.125 |
| HBV DNA positive | 42 (100.0%) | 4 (9.5%) | < 0.001 |
| HBsAg, log10 MU/mL | 3.2 (2.8–3.7) | 3.3 (2.3–3.6) | 0.695 |
| TE, kPa | 6.8 (5.3–11.1) | 5.4 (4.6–6.8) | < 0.001 |
| APRI | 0.30 (0.24–0.53) | 0.21 (0.17–0.28) | < 0.001 |
| FIB-4 | 1.11 (0.71–1.42) | 0.93 (0.54–1.52) | 0.001 |

APRI, the index ratio of aspartate aminotransferase to platelets; AVT, antiviral therapy; FIB-4, a four factor fibrosis index; HBeAg, infectivity antigen of hepatitis B virus; HBsAg, superficial antigen of hepatitis B virus; HBV DNA, deoxyribonucleinic acid of hepatitis B virus; TE, transient elastometry

The values are Ме (25th and 75th percentiles) or n/N (%)

**Table 2. Comparison of baseline parameters in the patients with and without a significant decrease of liver density**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **SRLD (n = 15)** | **No SRLD (n = 27)** | **P value** |
| Age, years | 55.0 (41.0–65.0) | 36.0 (27.0–55.0) | 0.015 |
| Gender | | | |
| Male | 5 (33.3%) | 18 (66.7%) | 0.038 |
| Female | 10 (66.7%) | 9 (33.3%) |
| HBeAg positive | 2 (13.3%) | 5 (18.5%) | 1.000 |
| HBV DNA, log10 MU/mL | 4.2 (3.3–5.5) | 4.7 (3.3–6.7) | 0.590 |
| HBsAg, log10 MU/mL | 3.2 (3.0–3.7) | 3.1 (1.8–4.3) | 1.000 |
| TE, kPа | 11.1 (7.0–20.9) | 5.9 (4.6–7.0) | < 0.001 |
| APRI | 0.42 (0.27–0.56) | 0.30 (0.22–0.45) | 0.265 |
| FIB-4 | 1.22 (1.05–2.40) | 0.97 (0.51–1.30) | 0.015 |
| Duration of the follow up, months | 19.0 (12.0–40.0) | 23.0 (17.0–29.0) | 0.673 |

APRI, the index ratio of aspartate aminotransferase to platelets; FIB-4, a four factor fibrosis index; HBeAg, infectivity antigen of hepatitis B virus; HBsAg, superficial antigen of hepatitis B virus; HBV DNA, deoxyribonucleinic acid of hepatitis B virus; SRLD, significant reduction of liver density; TE, transient elastometry

The values are Ме (25th and 75th percentiles) or n/N (%)

**Table 3. Factors associated with significant reduction of liver density on treatment with nucleoside and nucleotide analogues**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | **Unifactor analysis** | | | **Multiple regression analysis** | | |
| **OR** | **95% CI** | **P value** | **OR** | **95% CI** | **P value** |
| Age, years | 1.055 | 1.008–1.104 | 0.021 | 1.025 | 0.966–1.087 | 0.418 |
| Female gender | 4.000 | 1.049–15.260 | 0.042 | 5.144 | 0.833–31.785 | 0.078 |
| HBeAg positive | 0.677 | 0.114–4.004 | 0.667 |  |  |  |
| HBV DNA, log10 МU/mL | 1.171 | 0.792–1.731 | 0.428 |  |  |  |
| HBsAg, log10 МU/mL | 0.785 | 0.104–5.931 | 0.815 |  |  |  |
| Platelets, 109/L | 0.994 | 0.981–1.006 | 0.320 |  |  |  |
| ALT, U/L | 1.000 | 0.992–1.007 | 0.951 |  |  |  |
| AST, U/L | 1.002 | 0.991–1.012 | 0.754 |  |  |  |
| ТE, kPa | 1.354 | 1.081–1.697 | 0.008 | 1.324 | 1.029–1.702 | 0.029 |
| APRI | 1.127 | 0.570–2.230 | 0.730 |  |  |  |
| FIB-4 | 1.389 | 0.874–2.207 | 0.165 |  |  |  |
| Duration of the follow up, months | 1.003 | 0.965–1.043 | 0.862 |  |  |  |

ALT, alanine aminotransferase; APRI, the index ratio of aspartate aminotransferase to platelets; AST, aspartate aminotransferase; CI, confidence interval; FIB-4, a four factor fibrosis index; HBeAg, infectivity antigen of hepatitis B virus; HBsAg, superficial antigen of hepatitis B virus; HBV DNA, deoxyribonucleinic acid of hepatitis B virus; OR, odds ratio; TE, transient elastometry